Results of a phase I/II open‐label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

Publisher: John Wiley & Sons Inc

E-ISSN: 1365-2516|21|6|784-790

ISSN: 1351-8216

Source: HAEMOPHILIA, Vol.21, Iss.6, 2015-11, pp. : 784-790

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content